Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective

PharmacoEconomics

Volumn 30, Issue 2, 2012, Pages 87-101

  Duran, Aurea ^a   Sengupta, Nishan ^b   Diamantopoulos, Alexander ^c   Forster, Fiona ^a   Kwong, Louis ^d   Lees, Michael ^e  

^a IQVIA   (United States)

^b Worldwide Market Access   (United States)

^c Showa University Koto Hospital   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Bayer Healthcare   (United Kingdom)

Author keywords

Cost effectiveness; Rivaroxaban; Venous thromboembolism.

Indexed keywords

ENOXAPARIN; RIVAROXABAN;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; SURGICAL RISK; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; ENOXAPARIN; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; MORPHOLINES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84855886240     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11599370-000000000-00000     Document Type: Article

References (47)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6 Suppl.): 381-453S
2. Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003; 21 (7): 477-96 (Pubitemid 36560697)
3. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). Rockville (MD): U.S. Department of Health and Human Services, 2009 [online]. Available from URL: http://www.ahrq.gov/data/hcup [Accessed 2011 Jul 27]
4. Rivaroxaban (Xarelto) full prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc. 2011
5. Graff J, Von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47 (11): 1398-407 (Pubitemid 47624591)
6. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip ar-throplasty. N Engl J Med 2008; 358 (26): 2765-75 (Pubitemid 351930851)
7. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632): 31-9
8. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee ar-throplasty. N Engl J Med 2008; 358 (26): 2776-86 (Pubitemid 351930852)
9. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676): 1673-80
10. Friedman RJ, Gallus AS, Cushner FD, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008; 24 (1): 87-97 (Pubitemid 351160242)
11. Wells PS, Borah BJ, Sengupta N, et al. Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients. Am J Manag Care 2010; 16 (11): 857-63
12. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost 2011; 105 (3): 444-53
13. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82 (4): 423-8 (Pubitemid 28023279)
14. Centers for Medicare and Medicaid Services. FY 2009 IPPS final rule [online]. Available from URL: http://www.cms. gov/acuteinpatientpps/ipps2009 [Accessed 2011 Jul 27]
15. Centers for Medicare and Medicaid Services. Clinical lab fee schedule, health and human services [online]. Available from URL: http://www.cms.gov/ ClinicalLabFeeSched/02- clinlab.asp [Accessed 2011 Jul 27]
16. Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007; 5 (7): 1438-43 (Pubitemid 46965372)
17. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158 (14): 1525-31 (Pubitemid 28340985)
18. Arias E. United States life tables, 2006 [online]. Available from URL: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58- 21.pdf [Accessed 2011 Jul 27]
19. Diamantopoulos A, LeReun C, Rasul F, et al. Indirect comparison of rivaroxaban vs standard prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement. 13th Annual International Meeting, International Society for Pharma-coeconomics and Outcomes Research; 2008 May 3-7; Toronto (ON)
20. Diamantopoulos A, LeReun C, Rasul F, et al. Indirect comparisons of rivaroxaban versus alternative prophylaxes for the prevention of VTE in patients undergoing total knee replacement. American Society of Hematology, 50th Annual Meeting and Exposition; 2008 Dec 6-9; San Francisco (CA)
21. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91 (Pubitemid 27341818)
22. Thompson SG, Sharp SJ. Explaining heterogeneity in meta- analysis: a comparison of methods. Stat Med 1999; 18: 2693-708 (Pubitemid 29481404)
23. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350 (22): 2257-64
24. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349 (18): 1695-702 (Pubitemid 37315006)
25. Bureau of Labor Statistics. Consumer price index-all urban consumers [online]. Available from URL: http://data.bls. gov/cgi-bin/surveymost?cu [Accessed 2011 Jul 27]
26. AnalySource. AnalySource online: the online resource for drug pricing and deal information [online]. Available from URL: http://www.analysource.com [Accessed 2011 Jun 27]
27. Thomson Healthcare. Red book: pharmacy's fundamental reference. Montvale (NJ): Thomson Healthcare, 2008
28. Ingenix. DRG Expert: a comprehensive guidebook to the DRG classification system. Salt Lake City (UT): Igenix, 2008
29. McGarry LJ, Thompson D, Weinstein MC, et al. Cost ef- fectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Managed Care 2004; 10 (9): 632-42 (Pubitemid 39287373)
30. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Managed Care Pharm 2007; 13 (6): 475-86 (Pubitemid 350193368)
31. Gould MK, Dembitzer AD, Sanders GD, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. Ann Intern Med 1999; 130 (10): 789-99 (Pubitemid 29231147)
32. MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63 (20 Suppl.): S5-15 (Pubitemid 44672124)
33. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004; 93 (2): 259-62 (Pubitemid 38058748)
34. Darkow T, Vanderplas A, Lew K, et al. Treatment patterns and real-world effectiveness of warfarin in non-valvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005; 21 (10): 1583-94 (Pubitemid 41509186)
35. sanofi-aventis. Lovenox® (enoxaparin sodium injection) for subcutaneous and intravenous use: prescribing information [online]. Available from URL: http://products.sanofi. us/lovenox/lovenox.html [Accessed 2011 Jun 27]
36. Rasanen P, Paavolainen P, Sintonen H, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop 2007; 78: 108-15 (Pubitemid 46570266)
37. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997; 4: 49-56 (Pubitemid 127434425)
38. Haentjens P, De Groote K, Annemans L. Prolonged en- oxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a cost-utility analysis. Arch Orthop Trauma Surg 2004; 124: 507-17 (Pubitemid 39462470)
39. Diamantopoulos A, Lees M, Wells PS, et al. Cost- effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010; 104 (4): 760-70
40. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
41. Oster G, Tuden RL, Colditz GA. A cost-effectiveness anal- ysis of prophylaxis against deep-vein thrombosis in major orthopaedic surgery. JAMA 1987; 257 (2): 203-8 (Pubitemid 17207832)
42. Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur J Health Econ 2007; 8 (4): 313-23 (Pubitemid 350043708)
43. Sullivan SD, Kwong L, Nutescu E. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health 2006; 9 (2): 68-76 (Pubitemid 44044739)
44. Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivarox- aban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91 (5): 636-44
45. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10): 883-91
46. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26): 2499-510
47. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. Pharmacoeconomics 2009; 27 (10): 829-46